Pelthos Therapeutics (PTHS) FCF Margin (2025 - 2026)
Pelthos Therapeutics (PTHS) posted FCF Margin of 79.17% for Q2 2026, up 35.18% on a QoQ basis from 122.13% in Q1 2026.
Powered by 
Analysis
Pelthos Therapeutics (PTHS) FCF Margin (2025 - 2026) Analysis & Trends
Pelthos Therapeutics has reported FCF Margin for 2 years, with the latest figure at 79.17% in Q2 2026.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 79.17% in Q2 2026; TTM through Jun 2026 was 103.53%, a N/A change from a year earlier, with the FY2025 full-year figure at 135.09%, changed N/A from the prior year.
- FCF Margin was 79.17% for Q2 2026 at Pelthos Therapeutics, up from 122.13% in the prior quarter.
- The five-year high for FCF Margin was 68.75% in Q4 2025, with the low at 206.04% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 446.22 Bn | 439.65 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 357.04 Bn | 349.90 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 268.38 Bn | 260.69 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 156.32 Bn | 144.62 Bn | 10.94 Bn | 2.01% |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn | 25.52% |
| 7 | Revolution Medicines | 43.18 Bn | 43.18 Bn | - | - |
| 8 | Incyte | 24.85 Bn | 20.31 Bn | 1.57 Bn | 29.58% |
| 9 | United Therapeutics | 21.29 Bn | 18.62 Bn | 683.80 Mn | 26.25% |
| 10 | Pelthos Therapeutics | 80.38 Mn | 55.82 Mn | 21.23 Mn | -79.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -79.17% |
| Mar 31, 2026 | -122.13% |
| Dec 31, 2025 | -68.75% |
| Sep 30, 2025 | -206.04% |